Notably, the ADAURA study evaluated 3 years of adjuvant osimertinib in resected stage IB–IIIA EGFR Exon 19 deletion or L858R NSCLC and similarly, the ALINA trial looked at the use of adjuvant alectinib for two years in ALK rearranged NSCLC, both of which led to regulatory approvals and are part of standard of care management [8–11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.